THE CROHN’S DISEASE THERAPEUTICS MARKET SIZE WAS VALUED AT USD 12.82 BILLION IN 2021 AND IS EXPECTED TO REACH USD 23.14 BILLION BY 2027, GROWING AT A CAGR OF 10.35% DURING 2022-2027.

The global Crohn’s Disease Therapeutics Market Size, Share, Trends Analysis

  • Drug Class: TNF-Alpha inhibitors, 5-Aminosalicylates, and Others
  • Gender Type: Men and Women
  • Age Group: 49 yrs. & below and 50 yrs. & Above
  • Disease Type: Small/Large intestinal type, Large intestinal type, and Small intestinal type
  • Geography Type: North America, Europe, and APAC

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

232 Pages

icon-table

8 Tables

icon-chart

169 Charts

icon-region

3 Regions

icon-country

8 Countries

icon-company

10 Companies

icon-market

5 Market Segment

CROHN’S DISEASE THERAPEUTICS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 23.14 Billion
Market Size (2021) USD 12.82 Billion
CAGR (2022-2027) 10.35%
Base Year 2021
Forecast Year 2027
Market Segments Drug Class, Gender Type, Age Group, Disease Type, and Geography Type
Geographic Analysis North America, Europe, APAC

MARKET OVERVIEW

The Crohn’s disease therapeutics market is expected to grow at a CAGR of 10.35% from 2022 to 2027 and is expected to reach USD 23.14 billion by 2027 from USD 12.82 Billion in 2021. Crohn's disease is an inflammatory bowel disease (IBD) that causes digestive tract inflammation, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammatory bowel disease treatment market can be segmented into two types, i.e., Crohn's Disease and Ulcerative Colitis. Among these, Crohn's Disease dominates the global market.

According to Arizton estimates, the prevalence of Crohn's Disease was high in the United States, followed by the UK and China, in 2020. The increasing prevalence of Crohn's Disease is driving the growth of the Crohn's Disease drugs market. According to estimates, one million people were affected with Crohn's Disease in the US in 2019.

Crohn's Disease Therapeutics: Pipeline Scenario
The Crohn's Disease portfolio contains a total of 100+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for Crohn's Disease are in the Phase II stage. Anti-interleukin and integrin antibodies are dominating the Crohn’s Disease drug pipeline.

Crohn's Disease Therapeutics: Clinical Trials Scenario
 The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for Crohn's Disease are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Crohn's Disease have been in the early and mid-phases of development, with 75-80% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of global Crohn's Disease clinical trials.

MARKET DRIVERS:

Adoption of Biologics: Biological therapies such as anti-tumor necrosis factor (TNF), anti-interleukin & integrin antibodies are widely used for various inflammatory diseases such as Crohn’s disease (CD). These are considered generally satisfactory in treating patients who are not adequately controlled by steroids and aminosalicylates. Still, some patients can experience a loss of response to these therapies, particularly anti-TNFs. With Stelara (ustekinumab) being the last biologic approved for Crohn’s disease in 2016, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings and many new classes of therapies are looking to enter the industry over the next few years. The biologics such as anti-integrin and interleukin inhibitors are making inroads into the Crohn’s Disease market owing to better clinical profile and convenient patient dosing.

Increasing Prevalence of Crohn's Disease: The market studied has been witnessing considerable growth, which can be associated with the increasing prevalence of Crohn's Disease worldwide. As per estimates, the prevalence of Crohn's Disease patients was 18,30,704 in the 8MM in 2020. This number is expected to reach 21,91,344 from 2021 to 2027.

MARKET TRENDS:

The Emergence of Microbiome Therapeutics: microbiome-based therapeutics with novel mechanisms are emerging for treating Crohn’s Disease. Major players in the industry are developing novel products and spending significantly on research and development, along with major acquisitions and collaborations.
For example, Takeda has entered into a global licensing, co-development, and co-promotion agreement with Enterome S.A. Enterome, BiomX, Synlogics, 4D Pharma, Vedanta Bioscience, and many others are focusing on microbiome-based therapeutics for the treatment of the disease. These players adopt organic and inorganic growth strategies to strengthen their product portfolio.

Successive Launch of New Therapies: There are already several biologics indicated for the treatment of moderate-to-severe Crohn’s disease, including anti-TNFs Humira (adalimumab), Remicade (infliximab), and Cimzia (certolizumab pegol), the anti-integrins Entyvio (vedolizumab), and Tysabri (Natalizumab), and the interleukin (IL) 12 and 23 inhibitors Stelara (ustekinumab) and Skyrizi (Risankizumab-rzaa). Presently, five major companies have approved branded drugs in the Crohn’s Disease treatment market—Johnson & Johnson (J&J), AbbVie, Takeda, UCB, and Biogen.

MARKET SEGMENTATION

Drug Class: Among the drug class, TNF-Alpha inhibitors are expected to account for a significant share of the global Crohn's disease therapeutics market. However, the other drugs are expected to be the fastest growing segment during the forecast period. Recently approved biologics such as Skyrizi (risankizumab-rzaa) are expected to drive the global Crohn's Disease treatment market during the forecast period. The Crohn’s disease market has historically relied on anti-tumor necrosis factor (anti-TNF) therapies that have been available for over a decade. Still, recent developments have led to research on novel mechanisms of action (MOAs) to combat the high numbers of patients experiencing treatment non-response. The Crohn’s disease market will experience significant growth due mainly to the launch of new drugs, most of which are expected to launch between 2023–2025, targeting the moderate-to-severe patient population. The biologics such as anti-integrin and interleukin inhibitors are making inroads into the Crohn’s Disease market owing to better clinical profile and convenient patient dosing.

Gender type: Among the gender type, Women were expected to account for a significant share of the global Crohn's disease therapeutics market; this is because of slight women's predominance over men.

Disease type: Among the disease type, the small/large intestinal type is expected to account for a significant share of the global Crohn's Disease treatment market. However, the small intestinal type is expected to be the fastest growing segment during the forecast period.

Age Group: Among the Age group, People of age 49 yrs & below are expected to account for a significant share of the global Crohn’s Disease therapeutics market. The disease can occur at any age, but Crohn’s Disease is most often diagnosed in adolescents and adults between the ages of 20 and 30.

GEOGRAPHY ANALYSIS

The U.S. dominates Crohn’s disease therapeutics market by geography due to the rise in affordable healthcare, knowledge, and awareness amongst the people, and technological advancement in this region. However, the UK is expected to grow faster with a high CAGR in Crohn's Disease drug market due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.

COMPETITIVE SCENARIO

The Crohn's disease treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Crohn's Disease. The U.S. Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) for treating Crohn's Disease in 2012. Following this, the FDA approved Stelara (ustekinumab) in 2016 and Skyrizi (risankizumab-rzaa) in 2022 for treating Crohn's Disease. Although generic products continue to capture significant industry share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.

The prominent players offering drugs in the Crohn's Disease treatment market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, Gilead Bioscience, Celltrion, RedHill Biopharma, Landos Biopharma, ReiStone Biopharma, Eli Lilly and Company, and many others.

Key Mergers & Acquisitions:

  • In Mar 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals. Under the terms of the agreement, Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena.
  • In Jun 2021, Synlogic, Inc announced that it had entered into a research collaboration agreement with Roche to discover a novel Synthetic Biotic medicine for the treatment of inflammatory bowel disease (IBD). Under the terms of the deal, Synlogic and Roche will collaborate to develop a Synthetic Biotic drug addressing an undisclosed novel target in IBD.
  • In May 2021, Landos Biopharma, Inc and LianBio entered an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and selected Asian markets. Under the terms of the collaboration, LianBio will receive exclusive rights to develop and commercialize omilancor and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.

KEY MILESTONES

  • In June 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD). The approval was based on The ADVANCE and MOTIVATE studies designed to evaluate the efficacy and safety of two doses of risankizumab, 600 mg and 1200 mg, in adults with moderately to severely active Crohn's disease compared to placebo.
  • In May 2022, AbbVie announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to conventional or biologic therapy. The results showed that more patients treated with either dose of upadacitinib (15 mg or 30 mg once daily) achieved the co-primary endpoints of endoscopic response and clinical remission, as well as the secondary endpoint of endoscopic remission, at one year (week 52) compared to placebo.
  • In March 2022, Ossium Health, Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease. Ossium plans to initiate patient screening and enrollment in a multi-center Phase 1 clinical trial evaluating OSSM-001 by the end of 2022.

REPORT COVERAGE

  • Detailed overview of Crohn's Disease, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global trends of Crohn's Disease therapeutics market in the eight major markets (8MM)
  • Historical, current, and projected patient pool of Crohn's Disease for the 2018 – 2027 period
  • Gender type, Disease Type, Age Group, Drug Class, and Geography type segmentation of Crohn's Disease
  • Historical, current, and projected size of Crohn's Disease treatment market for the 2018 – 2027 period
  • In-depth analysis of the segments, which includes products, treatment, and competitor analysis
  • Market share of the key players, company profiles, product specifications, and competitive landscape
  • Comprehensive data on emerging trends, drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Crohn's Disease across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for Crohn's Disease across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across Crohn's Disease treatment market
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the Crohn's Disease space.

Frequently Asked Questions

How big is the global Crohn’s disease therapeutics market?

The global Crohn’s disease therapeutics market is expected to reach USD 23.14 billion by 2027.

What is the growth rate of the global Crohn’s disease therapeutics market?

The global Crohn’s disease therapeutics market is expected to grow at a CAGR of 10.35% from 2022 to 2027.

Who are the key players in the Crohn’s disease treatment market?

AbbVie Inc (AbbVie), Johnson & Johnson (J&J), Takeda Pharmaceutical Co Ltd (Takeda), Biogen Inc (Biogen), and UCB SA (UCB) are the key players in the Crohn’s disease treatment market.

What are the growth factors in the global Crohn’s disease therapeutics market?

The adoption of biologics and the increasing prevalence of Crohn's disease are the growth factors of the Crohn’s disease therapeutics market.

Which country holds the most extensive global Crohn’s disease therapeutics market share?

The U.S. dominated the global Crohn’s disease therapeutics market share.

Download Free Sample

The Crohn’s disease therapeutics market was valued at USD 12.82 billion in 2021 and is expected to reach USD 23.14 billion by 2027, growing at a CAGR of 10.35% during 2021-2027.

The following factors will drive the Crohn’s disease therapeutics market growth during the forecast period:

  • Adoption of Biologics
  • Increasing Prevalence of Crohn's Disease

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present Crohn’s disease therapeutics market and its dynamics for the forecasted period. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the industry. 

Key Vendors

  • AbbVie Inc (AbbVie)
  • Johnson & Johnson (J&J)
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • Biogen Inc (Biogen)
  • UCB SA (UCB)

Other Prominent Vendors

  • Boehringer Ingelheim International GmbH (Boehringer)
  • AstraZeneca Plc (AstraZeneca)
  • Bristol-Myers Squibb Co (BMS)
  • RedHill Biopharma Ltd
  • CellTrion

Segmentation by Drug Class

  • TNF-Alpha inhibitors
  • 5-Aminosalicylates
  • Others

Segmentation by Gender Type

  • Men
  • Women

Segmentation by Age Group

  • 49 yrs. & below
  • 50 yrs. & Above

Segmentation by Disease Type

  • Small/Large intestinal type
  • Large intestinal type
  • Small intestinal type

Segmentation by Geography

  • APAC
    • China
    • Japan
  • North America
    • United States
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy

CHAPTER – 1: CROHN’S DISEASE OVERVIEW
• Crohn’s Disease – An Overview

CHAPTER – 2: CROHN’S DISEASE EPIDEMIOLOGY & OVERVIEW
• 8MM: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• 8MM: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• 8MM: Historic & Projected Volume of incidence of Crohn’s Disease cases by Disease Type
• 8MM: Historic & Projected Volume of incidence of Crohn’s Disease cases by Severity Type
• 8MM: Historic & Projected Volume of Incidence of Crohn’s Disease cases by Gender & Age Group
• 8MM: Historic & Projected Volume of Prevalence of Crohn’s Disease cases by Disease type
• 8MM: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• 8MM: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• US: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• US: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• US: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• US: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• US: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• US: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• US: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• US: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• China: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• China: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• China: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• China: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• China: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• China: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• China: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• China: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• Japan: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• Japan: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• Japan: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• Japan: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• Japan: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• Japan: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• Japan: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• Japan: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• Germany: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• Germany: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• Germany: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• Germany: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• Germany: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• Germany: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• Germany: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• Germany: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• UK: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• UK: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• UK: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• UK: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• UK: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• UK: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• UK: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• UK: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• France: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• France: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• France: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• France: Historic & Projected Volume of incidence of Crohn’s Disease cases by Severity Type
• France: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• France: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• France: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• France: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• Italy: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• Italy: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• Italy: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• Italy: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• Italy: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• Italy: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• Italy: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• Italy: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group
• Spain: Historic & Projected Volume of Incidence & Prevalence of Crohn’s Disease
• Spain: Comparative Analysis of Incidence & Prevalence of Crohn’s Disease
• Spain: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Disease Type
• Spain: Historic & Projected Volume of incidence of Crohn’s Disease Cases by Severity Type
• Spain: Historic & Projected Volume of Incidence of Crohn’s Disease Cases by Gender & Age Group
• Spain: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Disease Type
• Spain: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Severity Type
• Spain: Historic & Projected Volume of Prevalence of Crohn’s Disease Cases by Gender & Age Group

CHAPTER – 3: CROHN’S DISEASE MARKET SIZE & OVERVIEW
• 8MM: Historic & Projected Revenue of Crohn’s Disease
• 8MM: Historic & Projected Revenue of Crohn’s Disease Snapshot
• 8MM: Major Approved Drugs in Crohn’s Disease
• 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• US: Historic & Projected Revenue of Crohn’s Disease
• US: Historic & Projected Revenue of Crohn’s Disease Snapshot
• US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• China: Historic & Projected Revenue of Crohn’s Disease
• China: Historic & Projected Revenue of Crohn’s Disease Snapshot
• China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• Japan: Historic & Projected Revenue of Crohn’s Disease
• Japan: Historic & Projected Revenue of Crohn’s Disease Snapshot
• Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• Germany: Historic & Projected Revenue of Crohn’s Disease
• Germany: Historic & Projected Revenue of Crohn’s Disease Snapshot
• Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• UK: Historic & Projected Revenue of Crohn’s Disease
• UK: Historic & Projected Revenue of Crohn’s Disease Snapshot
• UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• France: Historic & Projected Revenue of Crohn’s Disease
• France: Historic & Projected Revenue of Crohn’s Disease Snapshot
• France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• Italy: Historic & Projected Revenue of Crohn’s Disease
• Italy: Historic & Projected Revenue of Crohn’s Disease Snapshot
• Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class
• Spain: Historic & Projected Revenue of Crohn’s Disease
• Spain: Historic & Projected Revenue of Crohn’s Disease Snapshot
• Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Age Group & Drug Class

CHAPTER – 4: CROHN’S DISEASE MARKETED DRUGS OVERVIEW
• Crohn’s Disease Marketed Drugs – An Overview
• Crohn’s Disease Marketed Drugs – Summary

CHAPTER – 5: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW
• Crohn’s Disease Pipeline Drugs – An Overview
• Crohn’s Disease Pipeline Drugs – Snapshot
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Disease type
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Development Phase
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Route of Administration
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Mechanism of Action
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Molecule type
• Crohn’s Disease Pipeline Drugs Overview & Snapshot – By Geography type

CHAPTER – 6: CROHN’S DISEASE CLINICAL TRIALS OVERVIEW
• Crohn’s Disease Clinical Trials Overview Snapshot
• Crohn’s Disease Clinical Trials Overview – By Recruitment Status
• Crohn’s Disease Clinical Trials Overview – By Product type
• Crohn’s Disease Clinical Trials Overview – By Route of Administration
• Crohn’s Disease Clinical Trials Overview – By Molecule type
• Crohn’s Disease Clinical Trials Overview – By Geography type

CHAPTER – 7: CROHN’S DISEASE MARKET DYNAMICS
• Crohn’s Disease Therapeutics Market Drivers
• Crohn’s Disease Therapeutics Market Constraints
• Crohn’s Disease Therapeutics Market Trends

CHAPTER – 8: CROHN’S DISEASE COMPETITIVE LANDSCAPE
• Crohn’s Disease Competitive Landscape – Marketed Drugs
• Key Company Profiles
• Competitive Scenario of Crohn’s Disease therapeutics market
• Key Company Snapshot
• Crohn’s Disease Competitive Landscape – Pipeline Drugs
• Key Emerging Company Profiles
• Key Company Snapshot
• Other Key Company Profiles

CHAPTER – 9: CROHN’S DISEASE MISCELLANEOUS
• Key Tentative Drug Approvals Timeline
• Key Regulatory Designations
• Key Milestones
• Deals & Collaborations
• Inactive/Discontinued/Dormant Products

CHAPTER – 10: APPENDIX
• About Arizton
• Research Methodology
• List of Abbreviations

Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN US (2018 – 2027)
Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN US (2018 – 2020)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN US (2021 – 2027)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN US (2018 – 2027)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN US (2018 – 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN US (2018 – 2027)
Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN US (2018 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN US (2018 – 2027)
Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN CHINA (2018 – 2027)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN CHINA (2018 – 2020)
Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN CHINA (2021 – 2027)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN CHINA (2018 – 2027)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN CHINA (2018 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN JAPAN (2018 – 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN JAPAN (2018 – 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN JAPAN (2021 – 2027)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN JAPAN (2018 – 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN JAPAN (2018 – 2027)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN GERMANY (2018 – 2027)
Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN GERMANY (2018 – 2020)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN GERMANY (2021 – 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN GERMANY (2018 – 2027)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN GERMANY (2018 – 2027)
Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN UK (2018 – 2027)
Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN UK (2018 – 2020)
Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN UK (2021 – 2027)
Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN UK (2018 – 2027)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN UK (2018 – 2027)
Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN UK (2018 – 2027)
Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN UK (2018 – 2027)
Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN FRANCE (2018 – 2027)
Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN FRANCE (2018 – 2020)
Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN FRANCE (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN FRANCE (2018 – 2027)
Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN FRANCE (2018 – 2027)
Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN ITALY (2018 – 2027)
Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN ITALY (2018 – 2020)
Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN ITALY (2021 – 2027)
Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN ITALY (2018 – 2027)
Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN ITALY (2018 – 2027)
Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN SPAIN (2018 – 2027)
Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN SPAIN (2018 – 2020)
Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF CROHN’S DISEASE IN SPAIN (2021 – 2027)
Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CROHN’S DISEASE BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF CROHN’S DISEASE BY DISEASE TYPE IN SPAIN (2018 – 2027)
Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF CROHN’S DISEASE BY GENDER TYPE IN SPAIN (2018 – 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN US (2021 – 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 – 2027)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 – 2027)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN US (2021 – 2027)

Exhibit 112: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN CHINA (2021 – 2027)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 – 2027)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 – 2027)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 – 2027)
Exhibit 118: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN GERMANY (2021 – 2027)
Exhibit 119: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 120: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 – 2027)
Exhibit 121: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 – 2027)
Exhibit 122: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 123: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 – 2027)
Exhibit 124: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN JAPAN (2021 – 2027)
Exhibit 125: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 126: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 – 2027)
Exhibit 127: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 – 2027)
Exhibit 128: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 129: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 – 2027)
Exhibit 130: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN FRANCE (2021 – 2027)
Exhibit 131: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 132: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 – 2027)
Exhibit 133: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 – 2027)
Exhibit 134: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 135: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 – 2027)
Exhibit 136: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN ITALY (2021 – 2027)
Exhibit 137: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 138: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 – 2027)
Exhibit 139: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 – 2027)
Exhibit 140: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 141: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 – 2027)
Exhibit 142: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN UK (2021 – 2027)
Exhibit 143: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 144: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 – 2027)
Exhibit 145: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 – 2027)
Exhibit 146: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 147: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 – 2027)
Exhibit 148: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET IN SPAIN (2021 – 2027)
Exhibit 149: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 150: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 – 2027)
Exhibit 151: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 – 2027)
Exhibit 152: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 153: HISTORIC & PROJECTED REVENUE OF CROHN’S DISEASE THERAPEUTICS MARKET BY IN SPAIN (2021 – 2027)
Exhibit 154: MARKETED DRUGS OVERVIEW IN CROHN’S DISEASE TREATMENT MARKET
Exhibit 155: MARKETED DRUGS OVERVIEW SNAPSHOT IN CROHN’S DISEASE TREATMENT
Exhibit 156: PIPELINE DRUGS OVERVIEW IN CROHN’S DISEASE TREATMENT MARKET
Exhibit 157: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 158: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 159: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 160: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 161: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 162: CROHN’S DISEASE PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 163: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 164: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 165: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 166: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 167: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 168: CROHN’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 169: COMPETITIVE ASSESSMENT OF CROHN’S DISEASE TREATMENT MARKET

LIST OF TABLES

Table 1: KEY MARKET DRIVERS IN CROHN’S DISEASE TREATMENT MARKET
Table 2: KEY MARKET CONSTRAINTS IN CROHN’S DISEASE TREATMENT MARKET
Table 3: KEY MARKET TRENDS IN CROHN’S DISEASE TREATMENT MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN CROHN’S DISEASE
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN CROHN’S DISEASE
Table 6: KEY MILESTONES IN CROHN’S DISEASE TREATMENT MARKET
Table 7: KEY DEALS & COLLABORATIONS IN CROHN’S DISEASE TREATMENT MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN CROHN’S DISEASE TREATMENT

Select a license type that suits your business needs

single-user Single User Licence
$2800.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3196.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$3996.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1200.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

20%

Off

OFF

DAYS

HOURS

MINUTES

SECONDS

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date